Selexys Pharmaceuticals Corporation Report issue

For profit Phase 2
Founded: Oklahoma City OK United States (2002)
Status: Acquired by Novartis (2016)

Organization Overview

First Clinical Trial
2013
NCT01895361
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Reprixys Pharmaceutical Corporation

Active Ingredients

Drugs in Phase 2 Trials (1)

crizanlizumab (Adakveo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1